Skip to main content
. Author manuscript; available in PMC: 2022 Dec 22.
Published in final edited form as: Clin Genitourin Cancer. 2021 Aug 16;20(2):97–101. doi: 10.1016/j.clgc.2021.08.001

Figure 2.

Figure 2

Radiographic progression-free survival in mCRPC patients with extreme clinical response to bipolar androgen therapy. Kaplan-Meier estimate of radiographic progression-free survival (rPFS) in mCRPC patients treated with BAT. The median rPFS is estimated at 11.3 months (95% confidence interval: 7.9–25.0 months). 95% confidence interval showed in shaded area.